Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026

Same author

Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine-to-Human Live Heart Transplant.

Xenotransplantation·2026

Same author

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

bioRxiv : the preprint server for biology·2026

Same author

Unmet health care needs in immune thrombotic thrombocytopenic purpura survivors.

Research and practice in thrombosis and haemostasis·2026

Same author

Olfactory Receptor Activation Reduces Platelet Reactivity and Arterial Thrombosis Through Actin Cytoskeleton Remodeling.

Circulation·2026

Same author

Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study.

Blood vessels, thrombosis & hemostasis·2026

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy.

Michael A Cole¹, Nikhil Ranjan¹, Gloria F Gerber¹

¹Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD.

|October 2, 2024

Summary

This summary is machine-generated.

A new cell-based biosensor aids in diagnosing complement-mediated thrombotic microangiopathy (CM-TMA). This method identifies immunoglobulin M (IgM)-driven complement activation, offering insights into disease mechanisms and potential therapeutic targets.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jun 11, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Area of Science:

Immunology
Hematology
Cell Biology

Background:

Complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is a serious condition.
It is linked to genetic variations or antibodies affecting complement system proteins and regulators.
Current diagnostic methods may not fully capture all underlying mechanisms.

Purpose of the Study:

To develop novel cell-based complement biosensors for diagnosing CM-TMA.
To investigate the role of different complement pathways in CM-TMA pathogenesis.
To monitor the effectiveness of complement-targeted therapies.

Main Methods:

Engineered HEK293 cells lacking specific complement regulatory proteins (CD55, CD59, CD46) were used as biosensors.
These biosensors utilized autonomous bioluminescence for sensitive detection.
Complement pathway inhibitors were employed to dissect the activation pathways.

Main Results:

The biosensor array successfully detected complement activation in CM-TMA.
Immunoglobulin M (IgM)-driven classical pathway activation was identified in both active disease and remission phases.
This finding offers an explanation for CM-TMA cases without identified alternative pathway variants.

Conclusions:

Cell-based complement biosensors provide a sensitive diagnostic tool for CM-TMA.
The study suggests a breakdown in IgM immunologic tolerance contributes to a subset of CM-TMA.
These findings may guide the development of targeted therapies for CM-TMA.